Communiqués Johnson & Johnson Lima

Actions

JNJ

US4781601046

Temps réel estimé Cboe BZX Autres places de cotation 02:00:00 29/06/2024			Varia. 5j.	Varia. 1 janv.
146,4 ^USD	-0,03%		-0,46%	-4,75%

28/06	Johnson & Johnson annonce des résultats "positifs" dans une étude de stade avancé sur la myasthénie grave	MT
28/06	Le combo Rybrevant de l'unité J&J obtient l'approbation de l'UE	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	28/06	PU
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	28/06	PR
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	28/06	PU
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	28/06	BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	27/06	AQ
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06	AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.	24/06	AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	21/06	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	21/06	AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	20/06	PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	20/06	BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	20/06	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	18/06	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	17/06	BU
J&J commits five-year investment in Italian medicine manufacturing	17/06	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	17/06	AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma	17/06	AQ
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	15/06	PR
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	14/06	PU
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	14/06	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30